‡a
Author's Optimization of anti-microbials in the treatment of Cystic Fibrosis Pulmonary Exacerbations: II. Therapies for Allergic Bronchopulmonary Aspergillosis (ABPA)
‡a
Author's State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics
‡a
patientsandfamiliesexperiencewithpharmacistcareatcysticfibrosisfoundationaccreditedclinics
‡A
Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics
‡9
1
‡a
surveyofcurrenttreatmentpracticesforvenousthromboembolisminpatientswithcysticfibrosis
‡A
Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosis
‡9
1
‡a
stateoftheartincysticfibrosispharmacologyoptimizationofantimicrobialsinthetreatmentofcysticfibrosispulmonaryexacerbations1antimethicillinresistantstaphylococcusaureusmrsaantibiotics
‡A
State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics
‡9
1
‡a
optimizationofantimicrobialsinthetreatmentofcysticfibrosispulmonaryexacerbations2therapiesforallergicbronchopulmonaryaspergillosisabpa
‡A
Optimization of anti-microbials in the treatment of Cystic Fibrosis Pulmonary Exacerbations: II. Therapies for Allergic Bronchopulmonary Aspergillosis (ABPA)
‡9
1
